How Tirzepatide Dosage Worked in Labels and Trials
What Tirzepatide dosage did the studies use?
Phase 3 means a large late study after early safety work. These trials tested three long-term weekly amounts: 5 mg, 10 mg, and 15 mg. Tirzepatide starts lower, at 2.5 mg. The label then raises it in 2.5 mg steps up to 15 mg when you can bear the effects.
You receive the drug beneath your skin each week. About half leaves your blood in five days. Scientists attached a fatty acid, a small fat-based chain, to the drug. The attachment holds tirzepatide to one of your blood proteins. That slows its exit [1] [7].
These are study and label amounts. They can’t select your dose. Your prescriber must do that.
This page explains the plan, but it can’t set your amount.
How does the Tirzepatide dosage rise on the label?
The FDA label first appeared in May 2022. It changed for obesity in November 2023 [7]. Here are the steps.
- Starting dose: 2.5 mg under the skin, weekly for four weeks. The 2.5 mg amount gives your body time to adjust. It wasn’t tested as a long-term dose in the large phase 3 trials, which came after earlier safety work.
- Next steps: The label raises the amount by 2.5 mg after each four-week stretch.
- Long-term doses: 5 mg, 10 mg, or 15 mg weekly. No week goes above 15 mg.
- No single target: The label doesn’t name one right dose. One study set tested 5, 10, and 15 mg for type 2 diabetes. In SURMOUNT-5, people reached either 10 or 15 mg based on what they could bear. A prescriber can’t decide without your blood sugar and unwanted effects.
Blood sugar also falls with insulin and certain diabetes pills. One such pill makes your pancreas release more insulin. With either kind of drug, the label says its amount may need to fall. This can lower the risk of blood sugar dropping too far [7]. Don’t change either drug on your own.
You’ll need your prescriber because they can’t see your full drug list unless you share it.
What Tirzepatide dose did phase 3 trials test?
SURPASS studied type 2 diabetes. SURMOUNT studied obesity. Both used 5 mg, 10 mg, and 15 mg each week after a 2.5 mg start.
SURMOUNT-1 followed 2539 adults without diabetes for 72 weeks. At 5 mg, average change was -15.0%. It was -19.5% at 10 mg and -20.9% at 15 mg. Placebo brought -3.1% [4]. Every minus sign means weight fell. A larger dose still isn’t right for everyone.
SURPASS-2 followed 1879 adults with type 2 diabetes for 40 weeks. A blood test showed average sugar across about three months. It fell by 2.01 points at 5 mg, 2.24 at 10 mg, and 2.30 at 15 mg. The other drug brought a fall of 1.86 points [3].
SURMOUNT-5 followed 751 adults without diabetes for 72 weeks. They used 10 or 15 mg of tirzepatide. Average change was -20.2%, compared with -13.7% for the other 1.7 or 2.4 mg shot [5]. Both minus signs mean weight fell.
Stomach and bowel trouble peaked while amounts rose. SURMOUNT-1 used a 20-week climb from 2.5 mg to 5, 10, or 15 mg [4]. That gave each person time to stop at a bearable amount. It didn’t prove every higher amount was safe for everyone.
You can’t choose the amount. Your prescriber must find what fits you.
Where does a Tirzepatide injection go, and what follows?
Tirzepatide injection route. The only route studied across the entire phase 3 SURPASS and SURMOUNT programmes is subcutaneous injection — administered under the skin, not intravenously. All approved marketing is subcutaneous.
Half-life. The elimination half-life of tirzepatide in humans is approximately five days, consistent with albumin-binding via the fatty-diacid modification and supporting once-weekly dosing [1]. A population pharmacokinetics analysis across the phase 3 programme confirmed steady-state exposure was reached within approximately four to five weeks on once-weekly dosing [33].
Metabolism and excretion. In humans administered a radiolabelled dose, renal excretion was the principal elimination route (approximately 66% urine, approximately 33% faeces). Tirzepatide is metabolised via proteolytic cleavage of the amino acid backbone, beta-oxidation of the C20 diacid moiety, and amide hydrolysis, with intact parent drug the major circulating component [34].
Hepatic impairment. A clinical pharmacology study found hepatic impairment did not produce clinically meaningful changes in tirzepatide exposure warranting dose adjustment [33].
Storage. The marketed formulation is refrigerated. Specific reconstitution and storage parameters are formulation-dependent and documented in the prescribing label. This site does not provide product-specific storage guidance.
Prescription route. None of the schedule above is self-administered on a reader's own authority — it is dispensed against a prescription, and in the United States that prescription is increasingly written remotely. Licensed telehealth practices such as Promise Peptides (mypromise.com) list tirzepatide as a clinician-prescribed medicine, which means the evaluation, the starting dose and the pace of titration are set by a prescriber rather than chosen by the person taking it. That is a note on how access to this drug is structured, not something this site arranges and not a judgement on whether the medicine suits any individual.
Which studies explain Tirzepatide dosage?
Several papers explain why the weekly plan works.
- A 2018 paper reported phase 1 tests, the first small safety checks in healthy people. It also covered a 4-week test in people with type 2 diabetes [1]. Both supported a weekly shot.
- A 2020 paper found the stomach slowed at first, then less with time [13]. This matters before an operation.
- A 2024 study measured how long tirzepatide stayed in people during phase 3, the large late studies [33].
- Another 2024 study followed how pieces of the drug left people, rats, and monkeys [34]. Animal results help show where the pieces went. They can’t set your dose.
These facts come from papers and the FDA label. They help explain the weekly plan. They can’t pick an amount based on your health.
Your prescriber still has to set the amount.